Nuvation Bio Inc. (NUVB)
- Previous Close
2.6200 - Open
2.6300 - Bid 2.6300 x 3100
- Ask 2.7500 x 1300
- Day's Range
2.6190 - 2.7600 - 52 Week Range
0.9500 - 4.1600 - Volume
638,645 - Avg. Volume
1,328,695 - Market Cap (intraday)
661.234M - Beta (5Y Monthly) 1.37
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3500 - Earnings Date May 2, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.90
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.
www.nuvationbio.comRecent News: NUVB
Performance Overview: NUVB
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NUVB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NUVB
Valuation Measures
Market Cap
661.23M
Enterprise Value
54.03M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.09
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.54
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-9.65%
Return on Equity (ttm)
-12.03%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-75.8M
Diluted EPS (ttm)
-0.3500
Balance Sheet and Cash Flow
Total Cash (mrq)
611.21M
Total Debt/Equity (mrq)
0.66%
Levered Free Cash Flow (ttm)
-41.59M
Research Analysis: NUVB
Company Insights: NUVB
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: NUVB
Daily – Vickers Top Buyers & Sellers for 04/11/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 12/20/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 12/13/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 11/03/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.